2022
Targeting the vasculature in cardiometabolic disease
Boutagy NE, Singh AK, Sessa WC. Targeting the vasculature in cardiometabolic disease. Journal Of Clinical Investigation 2022, 132: e148556. PMID: 35289308, PMCID: PMC8920329, DOI: 10.1172/jci148556.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCardiometabolic diseasesCardiometabolic disease burdenOptimal medical therapyType 2 diabetesContext of atherosclerosisCardiometabolic changesCV morbidityEndothelial dysfunctionEjection fractionGlycemic controlHeart failureMedical therapyProinflammatory mediatorsVascular inflammationDisease burdenDisease progressionCardiovascular diseaseVascular remodelingPathological changesEpidemic proportionsVascular endotheliumMetabolic diseasesDiseaseVasculatureObesity
1996
Reduced Gene Expression of Vascular Endothelial NO Synthase and Cyclooxygenase-1 in Heart Failure
Smith C, Sun D, Hoegler C, Roth B, Zhang X, Zhao G, Xu X, Kobari Y, Pritchard K, Sessa W, Hintze T. Reduced Gene Expression of Vascular Endothelial NO Synthase and Cyclooxygenase-1 in Heart Failure. Circulation Research 1996, 78: 58-64. PMID: 8603506, DOI: 10.1161/01.res.78.1.58.Peer-Reviewed Original ResearchConceptsHeart failureCyclooxygenase-1Von Willebrand factorPacing-induced heart failureVentricular end-diastolic pressureEndothelial cellsEndothelium-dependent responsesEnd-diastolic pressureLeft ventricular pacingPeripheral blood vesselsDiastolic pressureVentricular pacingThoracic aortaClinical signsMongrel dogsWestern blottingBlood vesselsWillebrand factorArbitrary unitsEcNOSTotal RNADogsPresent studyFailureCells